SecBot SecBot
PRESS-RELEASE ·Filed Mar 10, 2026

IMA

ImageneBio, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The stock reaction is likely to be muted as the filing contains no clinical data readouts or near-term catalysts. Monitor upcoming SID meeting in May 2026 for preclinical data presentation and track enrollment progress in the ADAPTIVE trial for potential acceleration of the timeline.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$6.07
T+0 close · Mar 10, 2026 · via day close
Latest settled
−10.21%
T+60 · $5.45
Vs SPY
−21.90%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 10 $6.07entry
  2. T+1 · 8mo ago −0.99%α −0.88% · $6.01
  3. T+5 · 8mo ago −0.82%α +0.08% · $6.02
  4. T+20 · 7mo ago −24.71%α −24.56% · $4.57
  5. T+60 · 6mo ago −10.21%α −21.90% · $5.45
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ImageneBio reported its Q4 and full-year 2025 financial results, highlighting a strong cash position of $135.3 million post-merger and ongoing Phase 2b ADAPTIVE trial for IMG-007 in atopic dermatitis. While R&D spending decreased slightly, G&A expenses more than doubled due to merger-related and personnel costs, leading to a wider net loss. No revenue or earnings guidance was provided, and the company remains in clinical development with no near-term commercial catalysts.

Key Financial Metrics

Revenue
$800.0K
-77.1% YoY
EPS
$-9.64
Deal Value
$75.0M

Key Facts

  • Ended 2025 with $135.3 million in cash, up from $12.1 million in 2024, due to a reverse merger and $75 million private placement.
  • R&D expenses decreased to $3.3M in Q4 2025 from $3.8M in Q4 2024.
  • G&A expenses rose to $5.2M in Q4 2025 from $2.4M in Q4 2024, driven by merger costs and stock-based compensation.
  • Net loss widened to $6.9M in Q4 2025 from $4.8M in Q4 2024.
  • Full-year 2025 net loss was $45.3M vs. $36.6M in 2024; license revenue declined to $800K from $3.5M.
  • IMG-007 Phase 2b trial ongoing with topline data expected in 2027; protocol amendment submitted to expand dosing regimens.
  • No safety concerns reported; no cases of pyrexia, ulcers, or malignancies observed.

Financial Impact

License revenue declined 77% YoY to $800K; full-year net loss increased 24% to $45.3M. Cash position strengthened to $135.3M, sufficient to fund operations into late-stage trials.

revenuenet losscash positionoperating expenses

Risk Factors

  • Clinical development risk: IMG-007 is still in Phase 2b with topline data not expected until 2027.
  • Revenue concentration: License revenue dropped sharply from $3.5M to $800K, indicating reliance on non-core, one-time income sources.
  • Increasing G&A costs: Rising administrative expenses post-merger could pressure cash runway if not managed.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3252746

Track record

10 reports on IMA

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +27.94% at T+60 after the Aug 7, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $3.50 Now $3.20 −8.57% settles Feb 12
  2. Nov 9, 20267d ago 8-K Neutral 4/10 Entry $3.81 Now $3.20 −16.01% settles Feb 8
  3. Aug 7, 202614w ago EFFECT Bearish 5/10 Entry $5.69 to $4.10 Now $3.20 +43.76% ▲ +27.94% +25.81% vs SPY
  4. Jun 26, 202620w ago 8-K Neutral 3/10 Entry $6.07 to $4.85 Now $3.20 −47.28% ▼ −20.10% −24.48% vs SPY
  5. Apr 30, 202628w ago DEFA14A Neutral 3/10 Entry $5.66 to $5.76 Now $3.20 −43.46% ▲ +1.77% −1.30% vs SPY
  6. Apr 13, 202631w ago 8-K Bearish 6/10 Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
  7. Apr 13, 202631w ago Press Release Bearish 6/10 Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
  8. Apr 6, 202632w ago EFFECT Neutral 3/10 Entry $4.55 to $5.77 Now $3.20 −29.67% ▲ +26.81% +13.34% vs SPY
  9. Mar 17, 202634w ago Press Release Neutral 3/10 Entry $5.83 to $5.71 Now $3.20 −45.06% ▼ −1.97% −13.50% vs SPY
  10. Mar 10, 202635w ago Press Release Neutral 4/10 Viewing Entry $6.07 to $5.45 Now $3.20 −47.28% ▼ −10.21% −21.90% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens in 6h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 10, 2026